Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model

Mediators of Inflammation

Volumn 2019, Issue , 2019, Pages

  Shieh, Jiunn Min ^a   Tseng, Hui Yun ^b   Jung, Fang ^b   Yang, Shih Hsing ^b   Lin, Jau Chen ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ATROGIN 1; BLEOMYCIN; COLLAGEN; FIBRONECTIN; INTERLEUKIN 33; INTERLEUKIN 6; MUSCLE RING FINGER 1 PROTEIN; STAT3 PROTEIN;

AMPK SIGNALING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED LUNG INJURY; BODY WEIGHT CHANGE; CONTROLLED STUDY; FUNCTIONAL RESIDUAL CAPACITY; HISTOPATHOLOGY; IL 6 SIGNALING; LUNG FIBROSIS; LUNG FUNCTION; LUNG HOMOGENATE; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; MYOBLAST; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SKELETAL MUSCLE; TOTAL LUNG CAPACITY; WESTERN BLOTTING; ANIMAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; LUNG INJURY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; INTERLEUKIN-33; INTERLEUKIN-6; LUNG INJURY; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION;

EID: 85065562055     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2019/7947596     Document Type: Article

References (44)

1. Raghu G., Collard H. R., Egan J. J., Martinez F. J., Behr J., Brown K. K., Colby T. V., Cordier J. F., Flaherty K. R., Lasky J. A., Lynch D. A., Ryu J. H., Swigris J. J., Wells A. U., Ancochea J., Bouros D., Carvalho C., Costabel U., Ebina M., Hansell D. M., Johkoh T., Kim D. S., King te Jr, Kondoh Y., Myers J., Müller N. L., Nicholson A. G., Richeldi L., Selman M., Dudden R. F., Griss B. S., Protzko S. L., Schünemann H. J., ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 2011, 183, 6, 788-824, 10.1164/rccm.2009-040GL, 2-s2.0-79952717349, 21471066
2. King T. E. Jr., Pardo A., Selman M., Idiopathic pulmonary fibrosis. The Lancet 2011, 378, 9807, 1949-1961, 10.1016/S0140-6736(11)60052-4, 2-s2.0-82755161052, 21719092
3. Richeldi L., HRHR D., Spagnolo P., Luppi F., Cochrane Airways Group, Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database of Systematic Reviews 2003, 3, 10.1002/14651858.CD002880, 12917934
4. Raghu G., Depaso W. J., Cain K., Hammar S. P., Wetzel C. E., Dreis D. F., Hutchinson J., Pardee N. E., Winterbauer R. H., Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. American Review of Respiratory Disease 1991, 144, 2, 291-296, 10.1164/ajrccm/144.2.291, 2-s2.0-0026389762, 1859050
5. Collard H. R., Ryu J. H., Douglas W. W., Schwarz M. I., Curran-Everett D., King T. E. Jr, Brown K. K., Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest 2004, 125, 6, 2169-2174, 15189938, 10.1378/chest.125.6.2169, 2-s2.0-2942699911
6. King T. E. Jr, Behr J., Brown K. K., du Bois R. M., Lancaster L., de Andrade J. A., Stähler G., Leconte I., Roux S., Raghu G., BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2008, 177, 1, 75-81, 10.1164/rccm.200705-732OC, 2-s2.0-37849012578, 17901413
7. King T. E. Jr., Albera C., Bradford W. Z., Costabel U., Hormel P., Lancaster L., Noble P. W., Sahn S. A., Szwarcberg J., Thomeer M., Valeyre D., du Bois R. M., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. The Lancet 2009, 374, 9685, 222-228, 10.1016/S0140-6736(09)60551-1, 2-s2.0-67650349068, 19570573
8. Rafii R., Juarez M. M., Albertson T. E., Chan A. L., A review of current and novel therapies for idiopathic pulmonary fibrosis. Journal of Thoracic Disease 2013, 5, 1, 48-73, 10.3978/j.issn.2072-1439.2012.12.07, 2-s2.0-84876720282, 23372951
9. Agustí A. G. N., Sauleda J., Miralles C., Gomez C., Togores B., Sala E., Batle S., Busquets X., Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2002, 166, 4, 485-489, 10.1164/rccm.2108013, 2-s2.0-0037102380, 12186825
10. Cohen S., Nathan J. A., Goldberg A. L., Muscle wasting in disease: molecular mechanisms and promising therapies. Nature Reviews Drug Discovery 2015, 14, 1, 58-74, 10.1038/nrd4467, 2-s2.0-84925286847, 25549588
11. Park W. Y., Goodman R. B., Steinberg K. P., Ruzinski J. T., Frank Radella I. I., Park D. R., Pugin J., Skerrett S. J., Hudson L. D., Martin T. R., Cytokine balance in the lungs of patients with acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine 2001, 164, 10, 1896-1903, 10.1164/ajrccm.164.10.2104013, 2-s2.0-0035891593, 11734443
12. Park C. S., Chung S. W., Ki S. Y., Lim G.-I., Uh S.-T., Kim Y. H., Choi D. I., Park J. S., Lee D. W., Kitaichi M., Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. American Journal of Respiratory and Critical Care Medicine 2000, 162, 3, 1162-1168, 10.1164/ajrccm.162.3.9906007, 2-s2.0-0033829671, 10988147
13. Pedroza M., Schneider D. J., Karmouty-Quintana H., Coote J., Shaw S., Corrigan R., Molina J. G., Alcorn J. L., Galas D., Gelinas R., Blackburn M. R., Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS One 2011, 6, 7, article e22667, 10.1371/journal.pone.0022667, 2-s2.0-79960740114, 21799929
14. Zhou Y., Murthy J. N., Zeng D., Belardinelli L., Blackburn M. R., Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One 2010, 5, 2, article e9224, 10.1371/journal.pone.0009224, 2-s2.0-77949518257, 20169073
15. Qiu Z., Fujimura M., Kurashima K., Nakao S., Mukaida N., Enhanced airway inflammation and decreased subepithelial fibrosis in interleukin 6-deficient mice following chronic exposure to aerosolized antigen. Clinical and Experimental Allergy 2004, 34, 8, 1321-1328, 10.1111/j.1365-2222.2004.02013.x, 2-s2.0-4143119932, 15298576
16. Pantelidis P., Fanning G. C., Wells A. U., Welsh K. I., du Bois R. M., Analysis of tumor necrosis factor-α lymphotoxin-α tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2001, 163, 10.1164/ajrccm.163.6.2006064, 2-s2.0-0034993072, 11371414
17. Le T.-T. T., Karmouty-Quintana H., Melicoff E., Le T.-T. T., Weng T., Chen N.-Y., Pedroza M., Zhou Y., Davies J., Philip K., Molina J., Luo F., George A. T., Garcia-Morales L. J., Bunge R. R., Bruckner B. A., Loebe M., Seethamraju H., Agarwal S. K., Blackburn M. R., Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. Journal of Immunology 2014, 193, 7, 3755-3768, 10.4049/jimmunol.1302470, 2-s2.0-84907222985, 25172494
18. Kobayashi T., Tanaka K., Fujita T., Umezawa H., Amano H., Yoshioka K., Naito Y., Hatano M., Kimura S., Tatsumi K., Kasuya Y., Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis. Respiratory Research 2015, 16, 99, 10.1186/s12931-015-0261-z, 2-s2.0-84939538294, 26289430
19. Bonetto A., Aydogdu T., Kunzevitzky N., Guttridge D. C., Khuri S., Koniaris L. G., Zimmers T. A., STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 2011, 6, 7, article e22538, 10.1371/journal.pone.0022538, 2-s2.0-79960611800, 21799891
20. Min/+mouse. Pflügers Archiv-European Journal of Physiology 2009, 457, 5, 989-1001, 10.1007/s00424-008-0574-6, 2-s2.0-59849123303, 18712412
21. Sala D., Sacco A., Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Current Opinion in Clinical Nutrition and Metabolic Care. 2016, 19, 3, 1-6, 10.1097/MCO.0000000000000273, 2-s2.0-84963656297, 27023048
22. Zhang L., Pan J., Dong Y., Tweardy D. J., Dong Y., Garibotto G., Mitch W. E., Stat3 activation links a C/EBP δ to myostatin pathway to stimulate loss of muscle mass. Cell Metabolism 2013, 18, 3, 368-379, 10.1016/j.cmet.2013.07.012, 2-s2.0-84883485261, 24011072
23. Moussion C., Ortega N., Girard J. P., The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008, 3, 10, article e3331, 10.1371/journal.pone.0003331, 2-s2.0-53749093767, 18836528
24. Prefontaine D., Lajoie-Kadoch S., Foley S., Audusseau S., Olivenstein R., Halayko A. J., Lemiere C., Martin J. G., Hamid Q., Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. The Journal of Immunology 2009, 183, 8, 5094-5103, 19801525, 10.4049/jimmunol.0802387, 2-s2.0-75549084963
25. Beltrán C. J., Núñez L. E., Díaz-Jiménez D., Farfan N., Candia E., Heine C., López F., González M. J., Quera R., Hermoso M. A., Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2010, 16, 7, 1097-1107, 20014018, 10.1002/ibd.21175, 2-s2.0-77953721901
26. Li D., Guabiraba R., Besnard A. G., Komai-Koma M., Jabir M. S., Zhang L., Graham G. J., Kurowska-Stolarska M., Liew F. Y., McSharry C., Xu D., IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. The Journal of Allergy and Clinical Immunology 2014, 134, 6, 1422-1432.e11, 10.1016/j.jaci.2014.05.011, 2-s2.0-84919866420, 24985397
27. Xia J., Zhao J., Shang J., Li M., Zeng Z., Zhao J., Wang J., Xu Y., Xie J., Increased IL-33 expression in chronic obstructive pulmonary disease. American Journal of Physiology-Lung Cellular and Molecular Physiology 2015, 308, 7, L619-L627, 10.1152/ajplung.00305.2014, 2-s2.0-84926380049, 25595648
28. Yang S. H., Lin J. C., Wu S. Y., Huang K. L., Jung F., Ma M. C., Wang Hsu G. S., Jow G. M., Membrane translocation of IL-33 receptor in ventilator induced lung injury. PLoS One 2015, 10, 3, article e0121391, 10.1371/journal.pone.0121391, 2-s2.0-84926393107, 25815839
29. Nishida A., Andoh A., Imaeda H., Inatomi O., Shiomi H., Fujiyama Y., Expression of interleukin 1-like cytokine interleukin 33 and Its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 2010, 59, 4, 531-541, 10.1136/gut.2009.193599, 2-s2.0-77950789564, 19996325
30. Marvie P., Lisbonne M., L'Helgoualc'h A., Rauch M., Turlin B., Preisser L., Bourd-Boittin K., Théret N., Gascan H., Piquet-Pellorce C., Samson M., Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. Journal of Cellular and Molecular Medicine 2010, 14, 6B, 1726-1739, 10.1111/j.1582-4934.2009.00801.x, 2-s2.0-77955142252, 19508382
31. Limjunyawong N., Mitzner W., Horton M. R., A mouse model of chronic idiopathic pulmonary fibrosis. Physiological Reports 2014, 2, 2, article e00249, 10.1002/phy2.249, 24744912
32. Gasse P., Riteau N., Charron S., Girre S., Fick L., Pétrilli V., Tschopp J., Lagente V., VFJ Q., Ryffel B., Couillin I., Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. American Journal of Respiratory and Critical Care Medicine 2009, 179, 10, 903-913, 10.1164/rccm.200808-1274OC, 2-s2.0-65649140025, 19218193
33. Zuo F., Kaminski N., Eugui E., Allard J., Yakhini Z., Ben-Dor A., Lollini L., Morris D., Kim Y., DeLustro B., Sheppard D., Pardo A., Selman M., Heller R. A., Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proceedings of the National Academy of Sciences of the United States of America 2002, 99, 9, 6292-6297, 10.1073/pnas.092134099, 2-s2.0-18344396051, 11983918
34. Datta A., Scotton C. J., Chambers R. C., Novel therapeutic approaches for pulmonary fibrosis. British Journal of Pharmacology 2011, 163, 1, 141-172, 10.1111/j.1476-5381.2011.01247.x, 2-s2.0-79953728756, 21265830
35. Huaux F., Liu T., McGarry B., Ullenbruch M., Phan S. H., Dual roles of IL-4 in lung injury and fibrosis. The Journal of Immunology 2003, 170, 4, 2083-2092, 12574379, 10.4049/jimmunol.170.4.2083, 2-s2.0-0037442216
36. Yamauchi K., Kasuya Y., Kuroda F., Tanaka K., Tsuyusaki J., Ishizaki S., Matsunaga H., Iwamura C., Nakayama T., Tatsumi K., Attenuation of lung inflammation and fibrosis in CD69-deficient mice after intratracheal bleomycin. Respiratory Research 2011, 12, 1, 131, 10.1186/1465-9921-12-131, 2-s2.0-80053475925, 21970554
37. Vanoirbeek J. A. J., Rinaldi M., de Vooght V., Haenen S., Bobic S., Gayan-Ramirez G., Hoet P. H. M., Verbeken E., Decramer M., Nemery B., Janssens W., Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. American Journal of Respiratory Cell and Molecular Biology 2010, 42, 1, 96-104, 10.1165/rcmb.2008-0487OC, 2-s2.0-73949100714, 19346316
38. Arras M., Huaux F., Vink A., Delos M., Coutelier J. P., Many M. C., Barbarin V., Renauld J. C., Lison D., Interleukin-9 reduces lung fibrosis and type 2 immune polarization induced by silica particles in a murine model. American Journal of Respiratory Cell and Molecular Biology 2001, 24, 4, 368-375, 11306428, 10.1165/ajrcmb.24.4.4249, 2-s2.0-0035052521
39. 2levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific RING finger protein 1 (MuRF1). Journal of Biological Chemistry 2015, 290, 14, 9183-9194, 10.1074/jbc.M114.625715, 2-s2.0-84926432204, 25691571,
40. Gilhodes J. C., Julé Y., Kreuz S., Stierstorfer B., Stiller D., Wollin L., Quantification of pulmonary fibrosis in a bleomycin mouse model using automated histological image analysis. PLoS One 2017, 12, 1, article e0170561, 10.1371/journal.pone.0170561, 2-s2.0-85010383562, 28107543
41. Kuswanto W., Burzyn D., Panduro M., Wang K. K., Jang Y. C., Wagers A. J., Benoist C., Mathis D., Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. Immunity 2016, 44, 2, 355-367, 10.1016/j.immuni.2016.01.009, 2-s2.0-84956705644, 26872699
42. Steinberg G. R., Kemp B. E., AMPK in health and disease. Physiological Reviews 2009, 89, 3, 1025-1078, 10.1152/physrev.00011.2008, 2-s2.0-67650914230, 19584320
43. Greer E. L., Oskoui P. R., Banko M. R., Maniar J. M., Gygi M. P., Gygi S. P., Brunet A., The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. The Journal of Biological Chemistry 2007, 282, 41, 30107-30119, 10.1074/jbc.M705325200, 2-s2.0-34848861463, 17711846
44. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., Walsh K., Schiaffino S., Lecker S. H., Goldberg A. L., Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117, 3, 399-412, 15109499, 10.1016/S0092-8674(04)00400-3, 2-s2.0-11144356337